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Abstract The modulation of programmed cell death is a
common theme in the patho-physiology of inflammation and
infectious disease. The synthesis and secretion of an IgA1
protease is strictly associated with virulence of the Neisseria
species. Here, we report on the inhibition of tumor necrosis factor
K (TNFK)-mediated apoptosis of the human myelo-monocytic
cell line U937 by highly purified IgA1 protease. Apoptosis was
verified by the cell surface exposure of phosphatidyl serine and
by terminal transferase mediated end-labeling of fragmented
DNA. Interestingly, IgA1 protease specifically cleaved the TNF
receptor II (TNF-RII) on the surface of intact cells whereas
TNF-RI was not affected by the enzyme. Therefore, inhibition of
TNFK-mediated apoptosis might be correlated to specific
cleavage of the TNF-RII by neisserial IgA1 protease.
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1. Introduction
The genus Neisseria includes a variety of harmless commen-
sal species and two human speci¢c pathogens, Neisseria go-
norrhoeae and Neisseria meningitidis, the causative agents of
gonorrhea and bacterial meningitis, respectively. One out-
standing characteristic of the pathogenic Neisseria species as
well as the three clinically most important agents of bacterial
meningitis, i.e. N. meningitidis, Haemophilus in£uenzae, and
Streptococcus pneumoniae, is their ability to produce extracel-
lular IgA1 proteases [1,2]. Despite the obvious fact that IgA1
proteases strongly correlate with the virulence properties of
bacterial species [2], the precise function of IgA1 proteases
in pathogenesis is still elusive. It is believed that the primary
function of this sequence speci¢c endopeptidase in the infec-
tion process is to selectively cleave proline-rich sequences in
the hinge region of human IgA1 [3]. Previous in vitro studies
have shown that IgA1 protease is not required for gonococcal
colonization and invasion of epithelial cells [4]. It is therefore
possible that IgA1 protease functions in later stages of infec-
tion. IgA1 protease has been shown to cleave other substrates
including synaptobrevin and the human lysosome-associated
lamp-1 protein [3,5,6]. The biological signi¢cance of this
cleavage, however, remains unclear.
Programmed cell death plays a key role in the regulation of
the host immune response [7]; therefore modulation of apop-
tosis is a wide-spread mechanism exploited by various patho-
gens in order to facilitate tissue in¢ltration and/or to interfere
with the host immune system [8]. In the immune system ex-
ternal stimuli by cytokines such as tumor necrosis factor K
(TNFK) play a central role in initiating apoptotic events [9].
Furthermore, TNFK, originally identi¢ed by its ability to
cause hemorrhagic necrosis of speci¢c tumors [10], is now
known to play a pivotal role in protection against parasitic,
viral and bacterial infections [11]. Considering that the inter-
ference with TNFK-dependent processes would be an e¡ective
way to subvert the host immune response, we investigated the
possible role of neisserial IgA1 proteases in TNFK-dependent
signaling processes. Our studies revealed that puri¢ed IgA1
protease is capable of interfering with the TNFK response.
In this respect, we demonstrate by annexin staining of trans-
located phosphatidylserines as well as by terminal transferase
mediated end-labeling of fragmented DNA that TNFK-depen-
dent apoptosis is prevented by neisserial IgA1 protease. More-
over, we present evidence suggesting that the inhibition of
TNFK-dependent signaling is due to the enzymatic cleavage
of the receptor type II for TNFK by the neisserial IgA1 pro-
tease.
2. Materials and methods
2.1. Cell line and culture
The TNF-sensitive human myelo-monocytic cell line U937 was ob-
tained from the American Type Culture Collection (CRL 1593). Cells
were grown in RPMI 1640 medium supplemented with 10% (v/v) FCS
and 50 WM 2-mercaptoethanol.
2.2. IgGa1 protease puri¢cation
The enzyme was puri¢ed from recombinant Escherichia coli H2053
(UT5600/pC1857/pIP12) according to previously published proce-
dures [3]. The puri¢ed IgA1 migrated as a single band of 106 kDa
in a Coomassie-stained gel, indicating that this enzyme has been pu-
ri¢ed to homogeneity s 95% (data not shown). Analysis of the lipo-
polysaccharides (LPS) content of puri¢ed IgA1 protease were done
using the LAL-test according to the manufacturer’s protocol (Haemo-
chrom Diagnostika, Germany). The endotoxin concentrations were
estimated using a series of Control Standard Endotoxin dilutions.
Analysis of the LPS content of the IgA1 protease preparations using
the Limulus test showed that only negligible amounts of 910 pg/ml
were present.
2.3. Enzyme activity assay
For demonstration of enzyme activity 1 Wg of immunoglobulin A1
isolated from human sputum (Sigma, St. Louis, MO, USA) was in-
cubated with puri¢ed recombinant IgA1 protease (1 Wg/Wl) for 4 h at
37‡C. The proteins were separated by SDS electrophoresis on 10%
polyacrylamide gels and protein bands were visualized by silver stain-
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ing. According to this procedure, the enzymatic activity of heat dena-
tured (boiling for 20 min) IgA1 protease was estimated and revealed
to be completely destroyed. To determine the amount of antibody and
speci¢c inhibitor required for maximal inhibition of IgA1 protease
activity, either serial dilution of di¡erent anti-IgA1 protease antibod-
ies (AK130, mouse monoclonal), AK24 and AK25 (polyclonal rab-
bit), or peptide prolyl-boronic acid (a generous gift from A.G. Plaut,
New England Medical Center, MA, USA) were added to 0.1 Wg IgA1
protease and pre-incubated for at least 1 h at room temperature.
Following incubation of these mixtures with 1 Wg human IgA1 for
4 h at 37‡C, cleavage activity was analyzed in silver-stained SDS^
PAGE. The concentration which achieved maximal inhibition was
subsequently used in the TNFK cytotoxicity assays.
2.4. Assessment of TNFK-dependent cytotoxicity and apoptosis
Generally, U937 cells were seeded into 96-well culture plates at
2U105 in 100 Wl of culture medium. 20 ng/ml of recombinant human
TNFK (108 U/mg, Pharma Biotechnologie Hannover, Germany) with
or without the indicated amount of IgA1 protease were applied to
each well and incubated at 37‡C and 5% CO2. After over night in-
cubation analysis of cell viability was carried out using the addition of
3-(4,5-dimethylthiazol-2yl-)-2,5 diphenyl tetrazolium bromide (MTT)
as described earlier [12]. Optical density was measured with a test
wave length of 550 nm and a reference wave length of 620 nm using
a 96-well multiscanner autoreader (DigiScan, Asys Hitech GmbH,
Eugendorf, Austria). The cytotoxic activity of TNFK was estimated
by reduced absorbance compared to untreated control cells. Percent-
age of dead and viable target cells, respectively, was determined as
follows: Relative cell counts (%) = 100U(OD in treated wells/OD in
untreated control wells)3100. Each experiment was carried out at
least four times. Results are presented as mean þ S.D. of n = 12 of
one representative experiment. Detections of apoptotic cells were
done by annexin V-FITC staining of translocated phosphatidylserines
according to the manufacturer’s protocol (ApoAlert1 Annexin V
Apoptosis kit, Clontech, Palo Alto, CA, USA). DNA fragmentation
was assessed by catalytically incorporating £uorescein-12-dUTP at the
3P-OH DNA ends using the enzyme terminal deoxynucleotidyl trans-
ferase (TdT) (Promega, Mannheim, Germany), which forms a poly-
meric tail using the principle of the TUNEL assay [13] according to
the manufacturer’s protocol. Negative controls were treated identi-
cally but in the absence of the TdT enzyme. Positive controls were
treated with DNase I prior to TdT staining. Stained cells were sub-
sequently analyzed with a FACScan £ow cytometer (Beckton Dick-
inson, Heidelberg, Germany). The data collected with FACScan were
examined using the software CELLQUEST (Beckton Dickinson).
Dead cells were excluded on the basis of forward and side scatter.
2.5. Immunoprecipitation of TNF-RII
U937 cells were adjusted to 106/ml and either labeled with 35S
methionine or not. The cells were lysed in 500 Wl 50 mM Tris^HCl,
pH 7.4, 0.15 M NaCl, 10 mM EDTA, pH 8.0, 2% NP-40, 0.1 mM
Pefabloc, 2 Wg/ml leupeptin, 10 Wg/ml pepstatin on ice for 1 h. Follow-
ing incubation of the cell lysate with either 2.5 Wl of the rat mono-
clonal anti-TNF-RII antibody (clone 2B7/97, Biotrend, Ko«ln, Ger-
many) or 2.5 Wl of an isotype matched control antibody, the
immunocomplexes were precipitated using 20 Wl protein A/G-Sephar-
ose. After extensive washing with lysis bu¡er, the samples were solu-
bilized in loading bu¡er and separated on a 10% SDS^PAGE. 35S
methionine-labeled immunoprecipitates were detected by autoradiog-
raphy. Unlabeled immunocomplexes were blotted onto a PVDF-mem-
brane and probed with a goat polyclonal antibody speci¢c for the
extracellular domain of TNF-RII (Santa Cruz Biotech., Santa Cruz,
CA, USA). After incubation with the secondary antibody, a mono-
clonal anti-goat alkaline phosphatase conjugate (Sigma), TNF-RII
molecules were visualized by NBT/BCIP reaction.
3. Results
3.1. Neisserial IgA1 protease prevents U937 cells from
TNFK-mediated cytotoxicity
Human myelo-monocytic U937 cells have been reported to
respond to TNFK treatment with a cytopathic outcome
[14,15]. Initially, various concentrations of TNFK were used
to determine the dose-dependent response of U937 cells for
cell death. Because the cells were not synchronized apoptosis
occurred only in a fraction of the cell population. Therefore,
also the percentage of cell loss of TNFK-treated cells and the
percentage of proliferation of untreated cells varied. In our
hands, TNFK-treatment induced cell loss of about 20% to a
maximum of about 40%. After over night incubation, the
TNFK-mediated cell loss was monitored by MTT-treatment.
At a treatment of cells with 20 ng/ml TNFK, about 40% cell
loss was observed compared to untreated control cells (Fig.
1A). Therefore, in order to assess the e¡ect of IgA1 protease
of TNFK-dependent signaling processes, U937 cells were
treated with 20 ng/ml TNFK and di¡erent amounts of puri¢ed
IgA1 protease. As illustrated in Fig. 1B IgA1 protease-treat-
ment protected the cells from TNFK-mediated cytotoxicity in
a concentration dependent manner. When IgA1 protease was
applied at concentrations of 0.4^2 Wg/ml cell proliferation
could be observed as in TNFK-untreated control cells. This
e¡ect was strictly TNFK-dependent since treatment of the cells
with various amounts of IgA1 protease alone did not in£u-
ence cellular viability in any detectable way (data not shown).
Furthermore, to exclude any e¡ect of the LPS contaminants
in IgA1 protease preparations, TNFK-treated U937 cells were
incubated with various amounts of E. coli LPS. Even an ex-
cess amount of LPS did not in£uence the cellular TNFK re-
sponse (data not shown), indicating that the minor LPS con-
tamination of the puri¢ed IgA1 protease does not account for
the observed e¡ect.
3.2. IgA1 protease inhibits TNFK-induced phosphatidylserine
translocation
As an early event of apoptosis, most cell types translocate
the membrane phospholipid phosphatidylserine (PS) from its
normal location at the inner face of the plasma membrane in
non-apoptotic cells to the cell surface. Surface exposed PS can
be easily detected by a FITC conjugate of annexin V, which
Fig. 1. E¡ect of IgA1 protease on TNFK-mediated cytotoxicity. A:
Dose response e¡ect of TNFK on U937 cells. 2U105 cells were
treated over night with di¡erent concentrations of TNFK. B: Con-
centration dependent inhibition of TNFK-mediated cytotoxicity by
IgA1 protease. Cells were treated with 20 ng/ml TNFK and various
amounts of IgA1 protease. Cell viability was measured by the MTT
assay. All experiments were repeated for at least four times with
n = 12 each. The data shown give the mean þ S.D. of n = 12 of one
representative experiment. The data are presented as relative cell
counts based on untreated control cells which were set at 100%.
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has a strong, natural a⁄nity of PS [16]. Hence, apoptotic cells
can be readily identi¢ed by their speci¢c staining with annexin
V. For this purpose, TNFK cytotoxicity assays with U937
cells were performed and after staining with annexin V, the
cells were analyzed by FACS. The data obtained demon-
strated that treatment of U937 cells with TNFK resulted in
a cell fraction with strong annexin V staining (Fig. 2C). In the
presence of IgA1 protease, however, the annexin V positive
cell population was markedly decreased (Fig. 3D) indicating
that IgA1 protease protects U937 cells from TNFK-mediated
apoptosis.
3.3. IgA1 protease inhibits TNFK-induced DNA fragmentation
Endonucleolysis is a further key biochemical event of apop-
tosis, resulting in the cleavage of nuclear DNA into oligo-
nucleosome-sized fragments. U937 cells treated with 20 ng/
ml TNFK exhibited a positive signal for fragmented DNA
as assessed by the TUNEL assay and subsequent FACS anal-
ysis, however, IgA1 protease also diminished DNA fragmen-
tation in TNFK-mediated apoptosis (Fig. 3B).
3.4. Inhibition of TNFK-mediated apoptosis requires
enzymatically active IgA1 protease
To clarify whether the enzymatic activity is responsible for,
or at least involved in the activity exerted by IgA1 protease on
TNFK-treated cells, di¡erent methods were applied. First, the
IgA1 protease was denatured by extensive boiling and then
analyzed for enzymatic activity using its natural substrate
IgA1. Neither cleavage of IgA1 nor inhibition of TNFK-de-
pendent cytotoxicity was observed with the denatured enzyme
(data not shown).
In Neisseria-infected hosts [17] or in animals immunized
with IgA1 proteases [18], antibodies which speci¢cally neutral-
ize the enzymatic activity are produced. To con¢rm the re-
quirement of active IgA1 protease for the inhibition of cyto-
toxicity, several antibody preparations were used in
subsequent tests. The speci¢c monoclonal antibody AK130
was found to most e¡ectively inhibit the cleavage of human
IgA1. IgA1 protease was thus pre-incubated with serial dilu-
tions of AK130 for at least 1 h at 37‡C. The immune com-
plexes were then added to TNFK-treated cells. After overnight
incubation, the cytotoxic activity of TNFK was determined by
the number of remaining cells. As a result, TNFK-dependent
cytotoxicity was no longer inhibited indicating that inactiva-
tion of IgA1 protease by the antibody abolished its inhibitory
e¡ect in the cytotoxicity assay (Fig. 4).
Since IgA1 protease is a relatively large enzyme and may
therefore harbor additional functions, we intended to inhibit
the proteolytic activity of this enzyme using peptide prolyl
boronic acid as speci¢c inhibitor [19]. First, the amounts re-
quired for inhibition of enzymatic activity were determined.
As illustrated in Fig. 5A 10^100 WM of the peptide prolyl
boronic acid preparation almost completely inhibited the en-
zymatic degradation of human IgA1. Subsequently, TNFK-
treated and untreated cells were incubated with peptide prolyl
boronic acid to demonstrate that even high amounts of pep-
tide prolyl boronic acid did not in£uence cell viability or the
ability of the cells to respond to TNFK. These experiments
clearly indicated that peptide prolyl boronic acid interfered
with neither cellular viability (data not shown) nor TNFK-
dependent cytotoxicity (Fig. 5B). Based on these results,
IgA1 protease was pre-incubated with the speci¢c inhibitors
prior to incubation with TNFK-treated cells. Consistent with
Fig. 2. Inhibition of TNFK-induced annexin V staining by IgA1
protease. A: Unstained cells. B^D: U937 cells were stained with
Propidium iodide (PI) and Annexin V-FITC. Controls: A and B:
Untreated cells. C and D: U937 cells were exposed to 20 ng/ml
TNFK with (D) or without 2 Wg/ml IgA1 protease (C) for 6 h after
which cell labeling and subsequent FACS analysis were performed.
Description of quadrants: upper right: late apoptotic or necrotic,
lower left: viable cells, lower right: early apoptotic.
Fig. 3. Inhibition of TNFK-induced DNA fragmentation by IgA1
protease. A: Controls: (solid) Positive control, cells were treated
with DNase I, (dashed) negative control, untreated cells without
TdT enzyme. B: U937 cells treated as described in Fig. 2 were incu-
bated over night and fragmented DNA was subsequently detected
by TUNEL staining and FACS analysis. (dotted) Untreated cells,
(dashed) TNFK-treated cells, (solid) cells treated with TNFK and
IgA1 protease.
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the inhibition of IgA1 cleavage, the enzyme did not prevent
the TNFK-dependent cytotoxicity at prolyl boronic acid con-
centrations of 10^100 WM (Fig. 5B). Altogether, these results
provide evidence for a function of the enzyme’s proteolytic
activity in the inhibition of TNFK activity.
3.5. IgA1 protease cleaves TNF-RII
Since TNFK functions by binding to either or both TNF
receptors I and II (TNF-RI, TNF-RII), we speculated that
IgA1 protease might cleave one of the TNF receptors or
TNFK itself. IgA1 proteases represent highly speci¢c endo-
peptidases cleaving distinct proline-rich sequence motifs, par-
ticularly in the hinge region of human IgA1 [3]. We therefore
used the known cleavage motifs in a computer-based search
for putative cleavage sites in TNFK as well as in TNF-RI and
TNF-RII. The search revealed that the extracellular domain
of TNF-RII contains several proline-rich motifs similar to the
IgA1 protease consensus cleavage sequence. Thus, we assessed
the susceptibility of the TNF receptor type II to cleavage by
IgA1 protease. Initially, TNF-RII was immunoprecipitated
from cellular lysates with a monoclonal antibody from rat
speci¢c for the extracellular domain and incubated with re-
combinant IgA1 protease. After resolving the immunoprecipi-
tates by SDS^PAGE, TNF-RII molecules were detected by
autoradiography. As illustrated in Fig. 6, lanes 3 and 4, the
amount of V75 kDa receptor molecules decreased substan-
tially and an additional band appeared at V62 kDa (lane 4),
indicating cleavage by IgA1 protease. Next, we analyzed the
capability of IgA1 protease to cleave the native membrane
bound receptors on viable U937 cells. For this purpose,
U937 cells were treated over night with IgA1 protease. Cells
were then lysed and type II receptors were immunoprecipi-
tated using the speci¢c antibody. As a control, the type I
receptors were precipitated. Immunocomplexes were subse-
quently analyzed by Western blotting. Consistent with the
lack of putative IgA1 protease cleavage sites in TNF-RI, no
cleavage of this receptor was detected (Fig. 6, lanes 7 and 8).
In contrast, a cleavage product of the TNF-RII at V62 kDa
Fig. 5. Peptide prolyl boronic acid as speci¢c inhibitor of IgA1 pro-
tease activity. A: 1 Wg human IgA1 was treated with 20 ng IgA1
protease pre-incubated with the indicated amounts of inhibitor.
Cleavage activity could be inhibited almost completely using 10 WM
or 100 WM inhibitor. B: E¡ect of peptide prolyl boronic acid on the
inhibition of IgA1 protease activity in TNFK-dependent cytotoxicity
assays. Peptide prolyl boronic acid alone did not interfere with the
cellular TNF-response. In accordance with the inhibition pro¢le in
A, the e¡ect of IgA1 protease in the TNFK assay was abolished at
10^100 WM concentrations. Controls: TNFK-untreated cells, cells
treated with 20 ng/ml TNFK alone. Cell loss as well as cell prolifer-
ation were determined as described in Fig. 1.
Fig. 4. Inhibition of IgA1 protease activity by monoclonal antibody.
AK130 (2 Wg/ml) was used in TNFK-dependent cytotoxicity assays.
For this purpose, cells were treated with 20 ng/ml TNFK, 2 Wg/ml
IgA1 protease were pre-incubated with the indicated dilutions of
AK130 prior to adding to TNFK-treated cells. Cytotoxicity analysis
revealed a clear inhibition of the protease e¡ect on TNFK-treated
cells. Controls were TNFK-untreated cells, TNFK-treated cells for
TNFK-mediated cytotoxicity, e¡ect of antibody alone on TNFK-
treated cells, activity of IgA1 protease alone on TNFK-treated cells.
Cell loss as well as cell proliferation were determined as described
in Fig. 1.
Fig. 6. Cleavage of TNF-RII by IgA1 protease. Following immuno-
precipitation from cellular lysates with a monoclonal antibody spe-
ci¢c for the extracellular domain of TNF-RII the immunocomplexes
were incubated with (lane 4) or without (lane 3) IgA1 protease. As
it is shown in lane 4, a cleavage product of V62 kDa (arrowhead)
could be clearly detected. To evaluate the cleavage activity of IgA1
protease on native cells, U937 cells were treated with (lane 6 and 8)
or without (lane 5 and 7) IgA1 protease prior to cellular lysis and
immunoprecipitation with either a monoclonal antibody speci¢c for
TNF-RI (lane 7 and 8) or TNF-RII (lane 5 and 6). As shown in
lane 6 IgA1 protease is also active on viable cells thereby cleaving
TNF-RII (arrowhead), however as it was suggested ^ due to the
lack or proline-rich motifs ^ TNF-RI was not cleaved by IgA1 pro-
tease (lane 8). Lanes 1 and 2, immunoprecipitation with an isotype
matched control antibody.
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was clearly observed (lane 6). However, only partial cleavage
of the type II receptor molecules was seen, possibly due to the
high turn over rate of TNF-RII [20]. Thus, results from these
experiments indicated that inhibition of TNFK-dependent
apoptosis by IgA1 protease is associated with the speci¢c
proteolytic degradation of receptor type II for TNFK.
4. Discussion
Despite the fact that IgA1 proteases strongly correlate with
the virulence properties of bacterial species [2], the precise
function of IgA1 proteases in pathogenesis is still elusive.
The results shown here provide ¢rst evidence that neisserial
IgA1 protease is a de¢ned bacterial factor capable of prevent-
ing human monocytic cells from TNFK-induced apoptosis.
Furthermore, our data indicate that the enzymatic activity
of the IgA1 protease is directly involved in the inhibition of
TNFK-dependent apoptosis. We also demonstrate the cleav-
age of TNF-RII, but not TNF-RI, by puri¢ed IgA1 protease.
This strongly suggests that the observed e¡ect could be due to
speci¢c cleavage of TNF-RII although a causal link between
these two intriguing observations is still missing.
TNF-RI and TNF-RII, together with other similar type I
integral membrane proteins, constitute a distinct receptor
super-family which is characterized by multiple cysteine-rich
repeats in the extracellular domain [21]. The activation of
these receptors is thought to occur by aggregating two or
three receptor molecules on the cell surface upon binding of
the homotrimeric ligands. This extracellular complex leads to
an activation of the intracellular domains and ¢nally to
TNFK-mediated signal transduction via a complex network
of adapter proteins. Cleavage of TNF-RII by IgA1 protease
might prevent this activation process.
The extracellular portions of TNF receptor type I and II
exist also as soluble fragments [22,23]. This mechanism occurs
naturally in vivo by proteolytic cleavage of the complete ex-
tracellular part of the receptor from its transmembrane do-
main. The soluble forms speci¢cally bind TNFK, competing
for its binding to the cell surface TNF-R’s thus interfering
with the biological function of TNFK in an agonist^antago-
nist pattern. Moreover, shedding of TNF-R’s is used by the
cells to modulate TNF receptor expression [24]. In addition to
naturally occurring soluble TNF-R’s, some viruses utilize this
cellular mechanism to interfere with TNFK-activity [25,26].
However, concerning the cleavage of TNF-RII by IgA1 pro-
tease, a similar shedding mechanism is very unlikely. Soluble
TNF-R’s as well as similar viral proteins comprise all four
extracellular cysteine-rich domains which are necessary for
TNFK binding [27]. However, due to the cleavage product
of V62 kDa shown in Fig. 6 and on the basis of the known
amino acid sequence of TNF-RII [22] the cleavage site of
IgA1 protease appears to be located near the binding site
for TNFK in the ¢rst N-terminal cysteine-rich domain thus
leading to a receptor fragment which comprises only the
TNFK binding site and part of the ¢rst cysteine-rich domain.
This very small fragment might therefore not be able to bind
TNFK. So, we conclude that inhibition of TNFK-dependent
apoptosis is directly mediated by cleavage of the ligand-bind-
ing domain from cellular TNF-RII rather than by a shedding
mechanism.
Although the extracellular domains of the TNF receptors
exhibit similar structures, they share no homology between
the cytosolic domains [21]. This has led to the suggestion
that the two TNF receptor transduce distinct signals [28].
For example, the TNF-RI contains a death domain, whereas
the TNF-RII does not. It has also been shown that the intra-
cellular domain of TNF-RI recruits several signaling proteins
distinct from that of the TNF-RII [9]. However, due to the
co-expression of both types of receptors on most cells, a dis-
section of their distinct signaling properties has been di⁄cult.
It is generally accepted that most of the TNFK signals are
mediated through the receptor type I, particularly the signals
necessary for NF-UB activation and apoptosis [9]. However, it
has been shown recently that TNF receptor type II activates
NF-UB and induces apoptosis [29]. In this respect, our data
demonstrating inhibition of TNFK-dependent apoptosis puta-
tively by cleaving TNF-RII support and extend these obser-
vations.
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